Corporate News: Sysmex Corp
Stock Performance (Wednesday 21st)
| Item | Value |
|---|---|
| Closing price (02:34 PM CET) | JPY 1,960.5 |
| Daily change | +1.8 % |
| Current market capitalization | JPY 1.2 trillion |
| Current supply of shares | 605.2 million |
| 24‑hour trading volume | JPY 7.6 billion |
| Monthly change | +0.59 % |
| 200‑day simple moving average | JPY 1,564.19 |
| 52‑week high | JPY 2,012.5 (08/26/2026) |
| 52‑week low | JPY 1,246 (05/15/2026) |
Recent Corporate Developments
Product Launch: Sysmex introduced the UF‑1500 particle analyser, capable of processing up to 60 samples per hour. The device is designed for small laboratories and emphasizes compactness, high throughput, and integration with laboratory information systems (LIS) and electronic health records (EHR).
Strategic Focus: The company is expanding its portfolio of laboratory and point‑of‑care solutions. This strategy aligns with the industry trend toward automated, connected workflows that reduce manual microscopy and enhance result consistency.
Market Opportunity: The urinalysis market is expected to grow steadily. Sysmex is positioning itself to meet demand for kidney disease screening and infection assessment through reliable consumables and scalable diagnostic platforms.
Related Stock Activity (Past 24 Hours)
| Stock | Ticker | Daily Change | Current Price (JPY) | Market Capitalisation (JPY) | P/E Ratio |
|---|---|---|---|---|---|
| Shiseido | 4911.T | +1.95 % | 3,504 | 1.4 trillion | – |
| Fukuoka | 8354.T | –4.15 % | 7,084 | 1.4 trillion | 14.37 |
| Toho | 9602.T | +4.93 % | 1,676.5 | 1.4 trillion | 37.42 |
| Food & Life | 3563.T | –0.25 % | 5,930 | 1.4 trillion | 43.76 |
| Eisai | 4523.T | +0.91 % | 5,047 | 1.4 trillion | 33.03 |
Eisai Update
Eisai has reported progress in its research program for a novel therapeutic agent targeting neurological conditions. Early clinical evaluations indicate a measurable improvement in symptom control, with the treatment showing a modest reduction in disease activity compared to placebo. The regulatory agency has granted accelerated review status for the forthcoming filing. Eisai continues to refine dosing and safety profiles for the next phase of studies.
Company Overview
Sysmex Corp. is headquartered in Kobe, Japan, and specializes in the manufacturing of reagents and equipment for clinical tests, particularly hematologic and immune assays. The company also develops, manufactures, and trades particle analyzers, including blood coagulation analyzers, and provides related software solutions. Sysmex operates globally, with a presence in the United States, EMEA, China, and the Asia Pacific region. The initial public offering took place on November 15 1995. For additional information, visit www.sysmex.co.jp or trade on the Tokyo Stock Exchange.